Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...
Zacks.com on MSN4h
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADCGilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...
The stock's fall snapped an eight-day winning streak.
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...
Gilead Sciences (NASDAQ:GILD) shares continued gains for the eighth straight session, as the stock was up 1.5% on Monday. The ...
The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...
Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...
A judge Monday denied a bid by a former Gilead Sciences Inc. COO to transfer to Ventura County a sexual harassment lawsuit ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis Tuesday said they have entered into an option and license agreement to discover and ...
Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...
Gilead (GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback